All In Biotech

Drug Trial Radar · NCT05615974

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

A Phase I/II, Open-label, Dose Escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of LM-101 Injection as a Single Agent or Combination Therapy in Patients With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

139

Planned (sponsor's estimate)

Start

Jan 11, 2023

Primary completion

Jan 11, 2027

Study completion Jan 11, 2028

Sponsor

Lead sponsor
LaNova Medicines LimitedIndustry
Sponsor type
Industry
First posted
Nov 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors

Conditions

  • Malignant Tumors

Interventions

  • LM101Drug

    Administered intravenously

  • ToripalimabDrug

    Administered intravenously

  • RituximabDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: 48 weeks
  2. Incidence of dose-limitingtoxicity (DLT)Time frame: 48 weeks
  3. Incidence of serious adverse event (SAE)Time frame: 48 weeks
  4. Temperature in ℃Time frame: 48 weeks
  5. Pulse in BPM(Beat per Minute)Time frame: 48 weeks
  6. Blood Pressure in mmHgTime frame: 48 weeks
  7. Weight in KgTime frame: 48 weeks
  8. Height in centimeterTime frame: 48 weeks
  9. Laboratory tests-Blood Routine examinationTime frame: 48 weeks
  10. Laboratory tests-Urine Routine testTime frame: 48 weeks
  11. Laboratory tests-Blood biochemistryTime frame: 48 weeks
  12. Laboratory tests- Coangulation functionTime frame: 48 weeks
  13. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 48 weeks
  14. 12-lead electrocardiogram (ECG) in QTcF.Time frame: 48 weeks
  15. 12-lead electrocardiogram (ECG) in QT.Time frame: 48 weeks
  16. 12-lead electrocardiogram (ECG) in QRS.Time frame: 48 weeks
  17. 12-lead electrocardiogram (ECG) in HR.Time frame: 48 weeks
  18. 12-lead electrocardiogram (ECG) in RR.Time frame: 48 weeks
  19. 12-lead electrocardiogram (ECG) in PR.Time frame: 48 weeks
  20. ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 48 weeks
  21. Overall Response Rate (ORR)Time frame: 64 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, CMU

    Beijing, China · Terminated

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • Linyi Cancer Hospital

    Linyi, Shandong, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.